“Green is the prime color of the world, and that from which its loveliness arises”
Pedro Calderon de la Barca
GreenBone at Sme 2015
GREENBONE ORTHO SRL wants to become a worldwide leader for bone regeneration by providing innovative and easy to use bio-inspired solutions that will help cure severe diseases. The primary goal of GREENBONE is to develop a highly innovative bone implant, to generate biomimetic – reabsorbable – Bamboo-derived bone graft scaffold suitable to address non-union fractures and other very nasty skeleton damages.
Create value for our patients and our investors
GreenBone Ortho srl is a start up founded in 2014 and located in Faenza (Italy). GreenBone is developing a highly innovative, bone regenerating, load-bearing implants to treat severe fractures and conditions such as trauma and tumours that result in extensive bone loss. The company’s patented technology transforms Bamboo into an established, widely used biomaterial, hydroxyapatite, to provide a bone graft scaffold with unique and never achieved so far mechanical strength, weight bearing and bone regeneration properties needed for large implants. New functional bone formation with GreenBone has been demonstrated in vitro and in vivo. GreenBone will begin human studies early 2017 in patients with non-healing (non-union) critical size fractures. The company is led by a world class team that has advanced multiple orthopaedic products from bench-to-market.
GreenBone technology was conceived and developed by a research group at ISTEC-CNR in Faenza (Institute of Science and Technology for Ceramics).
First patent, filed in many territories, has been already granted in EU and China. Two new patents recently submitted. GreenBone Ortho srl and CNR entered a world wide exclusive license agreement (including right to acquire).
GreenBone closed a first round of investments for 3 million Euro from ZernikeMeta Ventures, Italian Angels for Growth (IAG) and some private Italian and foreign investors. ISTEC-CNR (Faenza) is one of the most advanced institutes of the National Research Council (CNR), focused on research on innovative materials for aerospace applications, biomedical and in the emerging field of green chemistry. ISTEC research originated several international patents which generated successful startups and various industrial collaborations.
Zernike and META is a financial Company specialized in finance for innovation and new ventures creation. Since 1987 have handled more than 200 million Euros for the seed and startup financing, investing between 200,000 and 1 million Euro in more than 250 companies, obtaining with 180 exits returns higher than the European sector average.
Italian Angels for Growth (IAG) is the major Italian Angel Group operating since 2007 in the development of new ventures. IAG has developed through its partners and the involvement of other operators, investments in venture capital for about 24 million Euro divided into 43 rounds of investment. IAG partners have contributed to the birth and growth of 28 innovative ventures.
GreenBone has already robust evidence in terms of bone formation and load bearing in different studies in-vitro and in-vivo.In addition, a scaled up GMP manufacturing line to support GLP development has been completed.Accordingly to our straight-forward development plan, we will complete the following steps by end of 2018
✓ CE mark
✓ Pre-clinical study in large animals
✓ Pilot human study in patients with critical size non-healing (non-union) fractures.
GreenBone patients are waiting for our solution
GreenBone has properties never achieved in large scaffold
GreenBone is better then current procedures
GreenBone has a short path to market
GreenBone in the Global Orthopedic Biomaterial market
A bone graft is a surgical procedure used to fix problems associated with bones or joints. Bone grafting is a common surgical procedure.
The term pseudoarthrosis or non-union is usually applied to fractures which do not consolidate within a period between 6 and 8 months. On the other hand, the term of delayed union indicates fractures which consolidate in a period longer than normal. Bone defects are very challenging in orthopaedic practice; they can result from a high-energy traumatic event, from large bone resection for different pathologies such as tumour or infection, or from the treatment of complex non-unions. They can be considered critical in relation to the skeletal segment involved and the length of bone loss: 3 cm for the forearm, 5 cm in the femur and tibia, 6 cm in the humerus.
The bone used in a bone graft can come from the patient body (autograft), donor (allograft), or could be entirely manmade. Once accepted by the patient, the bone graft provides a framework where new, living bone may grow.
The two most common types of bone grafts are:
· – allograft: this graft uses bone from a deceased donor or a cadaver that has been cleaned and stored in a tissue bank
· – autograft: graft made from a bone inside a patient’s body, such as the ribs or hips
No effective solutions exist today to treat severe conditions that result in extensive bone loss such as trauma, tumors and bone infections.
Quite often patients undergo multiple painful surgery with very long recovery time. Unfortunately, post-traumatic limb amputations among trauma patients are not uncommon.
The economic impact of non-union fracture is extremely relevant both on the healthcare system and the social costs.
Biomimetic Products like GreenBone reproduce both chemical composition and 3D architecture of natural tissues
Innovative wood-derived bone regeneritive load bearing grafts.
From natural wood to bone gratfs without loosing the 3D structure of the material along the process.
GreenBone is obtained by transformation of natural wood, selected on the basis of their structural similarity with the complex structure of bone in different anatomical regions.
In particular, Rattan has a channel-like porosity closely reproducing that of the human bone.
Hydroxyapatite is a major component and an essential ingredient of normal bone and teeth in mammals. It is one of few materials that are classed as bioactive, meaning that it will support bone ingrowth and osseointegration when used in orthopaedic, dental and maxillofacial applications. Hydroxyapatite is extensively used in orthopedic and dentistry as bone filler in different form such as granule, paddy and cement. As a result of chemico-physical transformation of natural wood, GreenBone graft is completely made of hydroxyapatite. Accordingly, GreenBone can be marketed in the US accordingly with the 510(K) premarket submission to FDA
Global Orthopedic Biomaterials market (US$)
Global Orthopaedic Biomaterials market is witnessing a steady growth rate and has huge opportunities to sustain such very positive trend.
Major vendors in the market are looking for new and advanced biomaterial products for better implantation, with longevity and an ability to withstand stress load.
Based on GreenBone properties and consequent expected application in different skeletal segments, our innovative materials can play an important role in the market segments of Synthetic Bone Substitutes, Bone Allograph and Machined Bones. All together these market segments represent more than 40% of the Global Orthopedic Biomaterials market.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.